Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Cancer. 2003 Sep 1;98(5):978-82.

Gemcitabine added to doxorubicin, bleomycin, and vinblastine for the treatment of de novo Hodgkin disease: unacceptable acute pulmonary toxicity.

Author information

  • 1James P. Wilmot Cancer Center, University of Rochester, 601 Elmwood Avenue, PO Box 704, Rochester, NY 14642, USA. Jonathan_Friedberg@urmc.rochester.edu

Abstract

BACKGROUND:

Gemcitabine is an effective treatment for recurrent Hodgkin disease (HD), with relatively minimal associated toxicity. The authors conducted a trial substituting this drug for dacarbazine in the standard regimen to form ABVG (doxorubicin, bleomycin, vinblastine, gemcitabine) for patients with newly diagnosed, high-risk HD.

METHODS:

Twelve patients (median age, 34 years) with advanced-stage de novo HD were enrolled. Standard doses of doxorubicin, bleomycin, and vinblastine were given for six cycles. Cohorts of three patients were enrolled and the dose of gemcitabine was escalated to identify the maximally tolerated dose in this combination.

RESULTS:

The maximally tolerated dose of gemcitabine was determined to be 800 mg/m(2) in this combination. Five patients developed clinically significant pulmonary toxicity. Three required hospitalization during the final two cycles of treatment. Pneumonitis could not be predicted with serial diffusion capacity for carbon monoxide (DECO) evaluations, and reversed after discontinuation of bleomycin in three patients and steroid therapy in two patients. All 12 patients are alive to date, and 4 patients have experienced disease progression.

CONCLUSIONS:

The bleomycin/gemcitabine combination should not be pursued for de novo HD due to significant pulmonary toxicity.

Copyright 2003 American Cancer Society.

PMID:
12942565
[PubMed - indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for John Wiley & Sons, Inc.
    Loading ...
    Write to the Help Desk